| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-632 | |
| Phytochemical name or plant extracts | Glycitein | |
| PMID | 26339345 | |
| Literature evidence | Glycitein is an O-methylated isoflavone which accounts for 5-10% of the total isoflavones in soy food products. Cell proliferation studies on the dietary phytoestrogen, glycitein against human breast carcinoma SKBR-3 cells showed that glycitein exhibits biphasic regulation on SKBR-3 cells. | |
| IUPAC name | 7-hydroxy-3-(4-hydroxyphenyl)-6-methoxychromen-4-one | |
| Phytochemicals’ class or type of plant extracts | Isoflavone | |
| Source of phytochemicals or plant Extracts | Glycine max | |
| Geographical availability | Amur, China North-Central, China South-Central, China Southeast, Hainan, Inner Mongolia, Japan, Khabarovsk, Korea, Laos, Manchuria, Nansei-shoto, Primorye, Qinghai, Taiwan, Thailand, Tibet, Vietnam, Xinjiang | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Prostate cancer, Stomach cancer | |
| Target gene or protein | Bcl-2, Bax, MAPK, STAT-3 | |
| Gene or Protein evidence | While genistein, resveratrol and glycitein all increased apoptosis and reduced the Bcl-2/Bax ratio, resveratrol reduced this ratio more than either genistein or glycitein. Mechanistically, accompanying ROS, glycitein can activate mitogen-activated protein kinase (MAPK) and inhibited the signal transducer and activator of transcription 3 (STAT3) and nuclear factor-kappaB (NF-κB) signaling pathways. | |
| Target pathways | MAPK/STAT3/NF-κB signaling pathways NF-κB signaling pathway | |
| IC50 | 36400 μM against SKBR-3 | |
| Potency | At concentrations of less than 10 mg/mL, cells respond to glycitein by increasing cell growth and de novo DNA synthesis whereas the addition of glycitein at concentrations greater than 30 mg/mL significantly inhibited cell growth and DNA synthesis in a dose-dependent manner. | |
| Cell line/ mice model | SKBR-3, MCF-7 | |
| Additional information | Glycitein induces reactive oxygen species-dependent apoptosis and G0/G1 cell cycle arrest through the MAPK/STAT3/NF-κB pathway in human gastric cancer cells On knockdown analysis, genistein, resveratrol and glycitein all reduced the Bcl-2/Bax ratio in the presence of apoptosis-inducing stimuli, and estrogen receptor (ER) alpha silencing had no effect on these reductions. Thus, glycitein has the potential to a novel targeted therapeutic agent for human gastric cancer. | |
| PubChem ID | 5317750 | |
| Additional PMIDs | 17200150 18419813 9950237 15159299 19800779 19589736 19321575 23286459 26339345 9681530 10227048 15105043 26059153 20517637 30916421 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:60450240-2 | |
| Safety | NA |